Literature DB >> 21282498

Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury.

Masanori Kawaguchi1, Masafumi Takahashi, Takeki Hata, Yuichiro Kashima, Fumitake Usui, Hajime Morimoto, Atsushi Izawa, Yasuko Takahashi, Junya Masumoto, Jun Koyama, Minoru Hongo, Tetsuo Noda, Jun Nakayama, Junji Sagara, Shun'ichiro Taniguchi, Uichi Ikeda.   

Abstract

Background- Inflammation plays a key role in the pathophysiology of myocardial ischemia/reperfusion (I/R) injury; however, the mechanism by which myocardial I/R induces inflammation remains unclear. Recent evidence indicates that a sterile inflammatory response triggered by tissue damage is mediated through a multiple-protein complex called the inflammasome. Therefore, we hypothesized that the inflammasome is an initial sensor for danger signal(s) in myocardial I/R injury. Methods and Results- We demonstrate that inflammasome activation in cardiac fibroblasts, but not in cardiomyocytes, is crucially involved in the initial inflammatory response after myocardial I/R injury. We found that inflammasomes are formed by I/R and that its subsequent activation of inflammasomes leads to interleukin-1β production, resulting in inflammatory responses such as inflammatory cell infiltration and cytokine expression in the heart. In mice deficient for apoptosis-associated speck-like adaptor protein and caspase-1, these inflammatory responses and subsequent injuries, including infarct development and myocardial fibrosis and dysfunction, were markedly diminished. Bone marrow transplantation experiments with apoptosis-associated speck-like adaptor protein-deficient mice revealed that inflammasome activation in bone marrow cells and myocardial resident cells such as cardiomyocytes or cardiac fibroblasts plays an important role in myocardial I/R injury. In vitro experiments revealed that hypoxia/reoxygenation stimulated inflammasome activation in cardiac fibroblasts, but not in cardiomyocytes, and that hypoxia/reoxygenation-induced activation was mediated through reactive oxygen species production and potassium efflux. Conclusions- Our results demonstrate the molecular basis for the initial inflammatory response after I/R and suggest that the inflammasome is a potential novel therapeutic target for preventing myocardial I/R injury.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21282498     DOI: 10.1161/CIRCULATIONAHA.110.982777

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  293 in total

1.  Inflammasome components Asc and caspase-1 mediate biomaterial-induced inflammation and foreign body response.

Authors:  Ahsan F Malik; Rafaz Hoque; Xinshou Ouyang; Ayaz Ghani; Enping Hong; Khadija Khan; Laura Beth Moore; Gilbert Ng; Fay Munro; Richard A Flavell; Yan Shi; Themis R Kyriakides; Wajahat Z Mehal
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-22       Impact factor: 11.205

2.  Inflammasomes in cardiovascular diseases.

Authors:  Nisha Jain Garg
Journal:  Am J Cardiovasc Dis       Date:  2011-09-10

3.  Prostaglandin E2 and an EP4 receptor agonist inhibit LPS-Induced monocyte chemotactic protein 5 production and secretion in mouse cardiac fibroblasts via Akt and NF-κB signaling.

Authors:  Timothy D Bryson; Jacob Ross; Edward Peterson; Pamela Harding
Journal:  Prostaglandins Other Lipid Mediat       Date:  2019-06-20       Impact factor: 3.072

4.  Inflammation and NLRP3 Inflammasome Activation Initiated in Response to Pressure Overload by Ca2+/Calmodulin-Dependent Protein Kinase II δ Signaling in Cardiomyocytes Are Essential for Adverse Cardiac Remodeling.

Authors:  Takeshi Suetomi; Andrew Willeford; Cameron S Brand; Yoshitake Cho; Robert S Ross; Shigeki Miyamoto; Joan Heller Brown
Journal:  Circulation       Date:  2018-11-27       Impact factor: 29.690

Review 5.  Fibroblasts in myocardial infarction: a role in inflammation and repair.

Authors:  Arti V Shinde; Nikolaos G Frangogiannis
Journal:  J Mol Cell Cardiol       Date:  2013-12-07       Impact factor: 5.000

Review 6.  Anti-inflammatory therapies in myocardial infarction: failures, hopes and challenges.

Authors:  Shuaibo Huang; Nikolaos G Frangogiannis
Journal:  Br J Pharmacol       Date:  2018-03-04       Impact factor: 8.739

Review 7.  Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure.

Authors:  Laura C O'Brien; Eleonora Mezzaroma; Benjamin W Van Tassell; Carlo Marchetti; Salvatore Carbone; Antonio Abbate; Stefano Toldo
Journal:  Mol Med       Date:  2014-06-12       Impact factor: 6.354

8.  Pharmacologic Inhibition of the NLRP3 Inflammasome Preserves Cardiac Function After Ischemic and Nonischemic Injury in the Mouse.

Authors:  Carlo Marchetti; Stefano Toldo; Jeremy Chojnacki; Eleonora Mezzaroma; Kai Liu; Fadi N Salloum; Andrea Nordio; Salvatore Carbone; Adolfo Gabriele Mauro; Anindita Das; Ankit A Zalavadia; Matthew S Halquist; Massimo Federici; Benjamin W Van Tassell; Shijun Zhang; Antonio Abbate
Journal:  J Cardiovasc Pharmacol       Date:  2015-07       Impact factor: 3.105

9.  The Cardiomyocyte as a Source of Cytokines in Cardiac Injury.

Authors:  Toshinori Aoyagi; Takashi Matsui
Journal:  J Cell Sci Ther       Date:  2011-12-01

Review 10.  Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases.

Authors:  Giacomo Emmi; Maria Letizia Urban; Massimo Imazio; Marco Gattorno; Silvia Maestroni; Giuseppe Lopalco; Luca Cantarini; Domenico Prisco; Antonio Brucato
Journal:  Curr Cardiol Rep       Date:  2018-06-14       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.